慢性閉塞性肺疾患治療薬の世界市場2023年-2027年

Technavioが発行した調査報告書(IRTNTR70733-23)
◆英語タイトル:Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027
◆商品コード:IRTNTR70733-23
◆発行会社(リサーチ会社):Technavio
◆発行日:2022年12月30日
◆ページ数:162
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥320,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥512,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の市場調査レポートでは、世界の慢性閉塞性肺疾患治療薬市場規模が2022年から2027年まで年平均6.09%成長し、6654.49百万ドルに達すると予測しています。当調査レポートでは、慢性閉塞性肺疾患治療薬の世界市場について調査し、エグゼクティブサマリー、市場状況、市場規模、過去の市場規模、ファイブフォース分析、製品別分析(併用療法、単剤療法)、販売チャネル別分析(病院薬局、小売薬局、オンライン薬局)、顧客状況、地域別状況(北米、ヨーロッパ、アジア太平洋、アメリカ、イギリス、カナダ、ドイツ、日本、その他地域)、推進要因・課題・動向、企業状況、企業分析などの内容を掲載しています。なお、当市場の主要企業には、AstraZeneca Plc、Exela Pharma Sciences LLC、GlaxoSmithKline Plc、Glenmark Pharmaceuticals Ltd.、Innoviva Inc.、Lupin Ltd.、Merck and Co. Inc.、Mundipharma International Ltd.、Novartis AG、Theravance Biopharma Inc.、Vertex Pharmaceuticals Inc.、Viatris Inc.、Boehringer Ingelheim International GmbH、Cadila Pharmaceuticals Ltd.などが含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模
・過去の市場規模
・ファイブフォース分析

・世界の慢性閉塞性肺疾患治療薬市場規模:製品別
- 併用療法慢性閉塞性肺疾患治療薬の市場規模
- 単剤療法慢性閉塞性肺疾患治療薬の市場規模

・世界の慢性閉塞性肺疾患治療薬市場規模:販売チャネル別
- 病院薬局の市場規模
- 小売薬局の市場規模
- オンライン薬局の市場規模

・顧客状況

・地域別状況
- 北米の慢性閉塞性肺疾患治療薬市場規模
- ヨーロッパの慢性閉塞性肺疾患治療薬市場規模
- アジア太平洋の慢性閉塞性肺疾患治療薬市場規模
- アメリカの慢性閉塞性肺疾患治療薬市場規模
- イギリスの慢性閉塞性肺疾患治療薬市場規模
- カナダの慢性閉塞性肺疾患治療薬市場規模
- ドイツの慢性閉塞性肺疾患治療薬市場規模
- 日本の慢性閉塞性肺疾患治療薬市場規模
- その他地域の慢性閉塞性肺疾患治療薬市場規模

・推進要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益・価格・競争・プロモーションなどの主要なパラメーターの分析から、複数のソースからのデータを研究、統合、総括の方法により、市場の詳細なイメージを提示します。また、業界における主要インフルエンサーを特定することにより、市場の様々な側面を提供します。提示される情報は包括的​​で信頼性が高く、一次・二次の広範囲な調査結果です。 Technavio社の市場調査レポートは、正確な市場の成長を予測するために、完璧な競争環境と定性的・定量的調査手法を用いた詳細なベンダー選定方法と分析を提供します。
❖ レポートの概要 ❖

Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027
Technavio has been monitoring the chronic obstructive pulmonary disease drugs market and is forecast to grow by $6654.49 mn during 2022-2027, accelerating at a CAGR of 6.09% during the forecast period. Our report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.

Technavio’s chronic obstructive pulmonary disease drugs market is segmented as below:

By Product
• Combination therapy
• Monotherapy

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the chronic obstructive pulmonary disease drugs market covers the following areas:
• Chronic obstructive pulmonary disease drugs market sizing
• Chronic obstructive pulmonary disease drugs market forecast
• Chronic obstructive pulmonary disease drugs market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global chronic obstructive pulmonary disease drugs market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global chronic obstructive pulmonary disease drugs market 2017 – 2021 ($ million)
o 4.2 Product Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Product – Market share 2022-2027 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 Combination therapy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Combination therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Combination therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Combination therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Combination therapy – Year-over-year growth 2022-2027 (%)
o 6.4 Monotherapy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Monotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Monotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Monotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Monotherapy – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Product
o Exhibit 42: Market opportunity by Product ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 43: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 45: Chart on Comparison by Distribution Channel
o Exhibit 46: Data Table on Comparison by Distribution Channel
o 7.3 Hospital pharmacies – Market size and forecast 2022-2027
o Exhibit 47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacies – Market size and forecast 2022-2027
o Exhibit 51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o 7.5 Online pharmacies – Market size and forecast 2022-2027
o Exhibit 55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 59: Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 63: Chart on Geographic comparison
o Exhibit 64: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 65: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 67: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 68: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 81: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 85: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 93: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 97: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 101: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 102: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 104: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 105: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 106: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 107: Matrix on vendor position and classification
o 12.3 AstraZeneca Plc
o Exhibit 108: AstraZeneca Plc – Overview
o Exhibit 109: AstraZeneca Plc – Product / Service
o Exhibit 110: AstraZeneca Plc – Key news
o Exhibit 111: AstraZeneca Plc – Key offerings
o 12.4 Boehringer Ingelheim International GmbH
o Exhibit 112: Boehringer Ingelheim International GmbH – Overview
o Exhibit 113: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 114: Boehringer Ingelheim International GmbH – Key news
o Exhibit 115: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 116: Boehringer Ingelheim International GmbH – Segment focus
o 12.5 Cadila Pharmaceuticals Ltd.
o Exhibit 117: Cadila Pharmaceuticals Ltd. – Overview
o Exhibit 118: Cadila Pharmaceuticals Ltd. – Product / Service
o Exhibit 119: Cadila Pharmaceuticals Ltd. – Key offerings
o 12.6 Cipla Ltd.
o Exhibit 120: Cipla Ltd. – Overview
o Exhibit 121: Cipla Ltd. – Business segments
o Exhibit 122: Cipla Ltd. – Key news
o Exhibit 123: Cipla Ltd. – Key offerings
o Exhibit 124: Cipla Ltd. – Segment focus
o 12.7 Exela Pharma Sciences LLC
o Exhibit 125: Exela Pharma Sciences LLC – Overview
o Exhibit 126: Exela Pharma Sciences LLC – Product / Service
o Exhibit 127: Exela Pharma Sciences LLC – Key offerings
o 12.8 GlaxoSmithKline Plc
o Exhibit 128: GlaxoSmithKline Plc – Overview
o Exhibit 129: GlaxoSmithKline Plc – Business segments
o Exhibit 130: GlaxoSmithKline Plc – Key offerings
o Exhibit 131: GlaxoSmithKline Plc – Segment focus
o 12.9 Lupin Ltd.
o Exhibit 132: Lupin Ltd. – Overview
o Exhibit 133: Lupin Ltd. – Product / Service
o Exhibit 134: Lupin Ltd. – Key news
o Exhibit 135: Lupin Ltd. – Key offerings
o 12.10 Merck and Co. Inc.
o Exhibit 136: Merck and Co. Inc. – Overview
o Exhibit 137: Merck and Co. Inc. – Business segments
o Exhibit 138: Merck and Co. Inc. – Key news
o Exhibit 139: Merck and Co. Inc. – Key offerings
o Exhibit 140: Merck and Co. Inc. – Segment focus
o 12.11 Mundipharma International Ltd.
o Exhibit 141: Mundipharma International Ltd. – Overview
o Exhibit 142: Mundipharma International Ltd. – Product / Service
o Exhibit 143: Mundipharma International Ltd. – Key offerings
o 12.12 Novartis AG
o Exhibit 144: Novartis AG – Overview
o Exhibit 145: Novartis AG – Business segments
o Exhibit 146: Novartis AG – Key offerings
o Exhibit 147: Novartis AG – Segment focus
o 12.13 Shionogi and Co. Ltd.
o Exhibit 148: Shionogi and Co. Ltd. – Overview
o Exhibit 149: Shionogi and Co. Ltd. – Product / Service
o Exhibit 150: Shionogi and Co. Ltd. – Key offerings
o 12.14 Sumitomo Pharma Co. Ltd.
o Exhibit 151: Sumitomo Pharma Co. Ltd. – Overview
o Exhibit 152: Sumitomo Pharma Co. Ltd. – Business segments
o Exhibit 153: Sumitomo Pharma Co. Ltd. – Key offerings
o Exhibit 154: Sumitomo Pharma Co. Ltd. – Segment focus
o 12.15 Teva Pharmaceutical Industries Ltd.
o Exhibit 155: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 156: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 157: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 158: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 159: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.16 Theravance Biopharma Inc.
o Exhibit 160: Theravance Biopharma Inc. – Overview
o Exhibit 161: Theravance Biopharma Inc. – Product / Service
o Exhibit 162: Theravance Biopharma Inc. – Key offerings
o 12.17 Viatris Inc.
o Exhibit 163: Viatris Inc. – Overview
o Exhibit 164: Viatris Inc. – Business segments
o Exhibit 165: Viatris Inc. – Key offerings
o Exhibit 166: Viatris Inc. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 167: Inclusions checklist
o Exhibit 168: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 169: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 170: Research methodology
o Exhibit 171: Validation techniques employed for market sizing
o Exhibit 172: Information sources
o 13.5 List of abbreviations
o Exhibit 173: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Product
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global chronic obstructive pulmonary disease drugs market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Product – Market share 2022-2027 (%)
Exhibits31: Data Table on Product – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Product
Exhibits33: Data Table on Comparison by Product
Exhibits34: Chart on Combination therapy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Combination therapy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Combination therapy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Combination therapy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Monotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Monotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Monotherapy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Monotherapy – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Product ($ million)
Exhibits43: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits44: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Distribution Channel
Exhibits46: Data Table on Comparison by Distribution Channel
Exhibits47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits59: Market opportunity by Distribution Channel ($ million)
Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits63: Chart on Geographic comparison
Exhibits64: Data Table on Geographic comparison
Exhibits65: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits67: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits68: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits101: Market opportunity By Geographical Landscape ($ million)
Exhibits102: Impact of drivers and challenges in 2022 and 2027
Exhibits103: Overview on Criticality of inputs and Factors of differentiation
Exhibits104: Overview on factors of disruption
Exhibits105: Impact of key risks on business
Exhibits106: Vendors covered
Exhibits107: Matrix on vendor position and classification
Exhibits108: AstraZeneca Plc – Overview
Exhibits109: AstraZeneca Plc – Product / Service
Exhibits110: AstraZeneca Plc – Key news
Exhibits111: AstraZeneca Plc – Key offerings
Exhibits112: Boehringer Ingelheim International GmbH – Overview
Exhibits113: Boehringer Ingelheim International GmbH – Business segments
Exhibits114: Boehringer Ingelheim International GmbH – Key news
Exhibits115: Boehringer Ingelheim International GmbH – Key offerings
Exhibits116: Boehringer Ingelheim International GmbH – Segment focus
Exhibits117: Cadila Pharmaceuticals Ltd. – Overview
Exhibits118: Cadila Pharmaceuticals Ltd. – Product / Service
Exhibits119: Cadila Pharmaceuticals Ltd. – Key offerings
Exhibits120: Cipla Ltd. – Overview
Exhibits121: Cipla Ltd. – Business segments
Exhibits122: Cipla Ltd. – Key news
Exhibits123: Cipla Ltd. – Key offerings
Exhibits124: Cipla Ltd. – Segment focus
Exhibits125: Exela Pharma Sciences LLC – Overview
Exhibits126: Exela Pharma Sciences LLC – Product / Service
Exhibits127: Exela Pharma Sciences LLC – Key offerings
Exhibits128: GlaxoSmithKline Plc – Overview
Exhibits129: GlaxoSmithKline Plc – Business segments
Exhibits130: GlaxoSmithKline Plc – Key offerings
Exhibits131: GlaxoSmithKline Plc – Segment focus
Exhibits132: Lupin Ltd. – Overview
Exhibits133: Lupin Ltd. – Product / Service
Exhibits134: Lupin Ltd. – Key news
Exhibits135: Lupin Ltd. – Key offerings
Exhibits136: Merck and Co. Inc. – Overview
Exhibits137: Merck and Co. Inc. – Business segments
Exhibits138: Merck and Co. Inc. – Key news
Exhibits139: Merck and Co. Inc. – Key offerings
Exhibits140: Merck and Co. Inc. – Segment focus
Exhibits141: Mundipharma International Ltd. – Overview
Exhibits142: Mundipharma International Ltd. – Product / Service
Exhibits143: Mundipharma International Ltd. – Key offerings
Exhibits144: Novartis AG – Overview
Exhibits145: Novartis AG – Business segments
Exhibits146: Novartis AG – Key offerings
Exhibits147: Novartis AG – Segment focus
Exhibits148: Shionogi and Co. Ltd. – Overview
Exhibits149: Shionogi and Co. Ltd. – Product / Service
Exhibits150: Shionogi and Co. Ltd. – Key offerings
Exhibits151: Sumitomo Pharma Co. Ltd. – Overview
Exhibits152: Sumitomo Pharma Co. Ltd. – Business segments
Exhibits153: Sumitomo Pharma Co. Ltd. – Key offerings
Exhibits154: Sumitomo Pharma Co. Ltd. – Segment focus
Exhibits155: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits156: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits157: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits158: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits159: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits160: Theravance Biopharma Inc. – Overview
Exhibits161: Theravance Biopharma Inc. – Product / Service
Exhibits162: Theravance Biopharma Inc. – Key offerings
Exhibits163: Viatris Inc. – Overview
Exhibits164: Viatris Inc. – Business segments
Exhibits165: Viatris Inc. – Key offerings
Exhibits166: Viatris Inc. – Segment focus
Exhibits167: Inclusions checklist
Exhibits168: Exclusions checklist
Exhibits169: Currency conversion rates for US$
Exhibits170: Research methodology
Exhibits171: Validation techniques employed for market sizing
Exhibits172: Information sources
Exhibits173: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 慢性閉塞性肺疾患治療薬の世界市場2023年-2027年(Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆